TP53TG5 inhibitors are a class of chemical compounds specifically designed to target and modulate the activity of the TP53TG5 protein, which is involved in intricate cellular processes. These inhibitors typically function by binding to the active site of the TP53TG5 protein, preventing the natural substrates or ligands from interacting with it, thereby blocking its normal biological function. In some cases, TP53TG5 inhibitors may bind to allosteric sites, regions on the protein distant from the active site, which can induce conformational changes that reduce or inhibit the protein's activity. The interaction between these inhibitors and the TP53TG5 protein is driven by non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions. These interactions are essential for stabilizing the inhibitor-protein complex and ensuring the effective inhibition of the TP53TG5 protein.
Structurally, TP53TG5 inhibitors exhibit considerable diversity, with designs ranging from small organic molecules to more complex chemical frameworks. These inhibitors often include functional groups such as hydroxyl, carboxyl, or amine groups, which are critical for interacting with key residues in the TP53TG5 protein's binding pockets. Aromatic rings and heterocycles are commonly used to enhance hydrophobic interactions with non-polar regions of the protein, while polar functional groups allow for hydrogen bonding with polar amino acids. The physicochemical properties of TP53TG5 inhibitors, such as molecular weight, solubility, lipophilicity, and polarity, are finely tuned to ensure optimal binding affinity and stability in different biological environments. Hydrophobic regions within the inhibitors help stabilize interactions with non-polar areas of the protein, while polar regions ensure solubility and interaction with polar residues, creating a balance that optimizes the inhibitors' performance in modulating TP53TG5 activity. This careful optimization ensures that TP53TG5 inhibitors can effectively influence the protein's function while maintaining structural integrity in varying conditions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Nutlin-3 antagonizes MDM2, leading to enhanced TP53 activity which could downregulate the expression of proteins targeted by TP53. | ||||||
Pifithrin-α hydrobromide | 63208-82-2 | sc-45050 sc-45050A | 5 mg 25 mg | $118.00 $287.00 | 36 | |
Pifithrin-α(HBr) inhibits p53, potentially reducing the transcriptional activation of p53 target genes and their protein products. | ||||||
p53 Activator III, RITA | 213261-59-7 | sc-202753 sc-202753A sc-202753B sc-202753C | 1 mg 10 mg 100 mg 500 mg | $110.00 $268.00 $1533.00 $5103.00 | 9 | |
RITA binds to p53, preventing it from interacting with MDM2; this could decrease levels of certain p53-regulated proteins. | ||||||
Tenovin-6 | 1011557-82-6 | sc-224296 sc-224296A | 1 mg 5 mg | $272.00 $1214.00 | 9 | |
Tenovin-6 increases p53 levels by inhibiting SIRT1 and SIRT2, potentially reducing the expression of some p53 target proteins. | ||||||
PRIMA-1MET | 5291-32-7 | sc-361295 sc-361295A | 10 mg 25 mg | $150.00 $319.00 | 5 | |
APR-246 restores wild-type p53 conformation, which might affect the expression of p53 target proteins. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin causes DNA damage that activates p53, potentially modulating the expression of downstream target proteins. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil induces DNA damage leading to p53-mediated cellular responses, possibly influencing p53 target protein levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin induces DNA damage and p53 activation, which could lead to a decrease in certain p53-regulated proteins. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin, by causing DNA damage, can activate p53 which may in turn suppress the expression of some p53 target proteins. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide causes DNA damage and p53 activation, which could affect the expression of downstream p53-regulated proteins. | ||||||